Maternal RSV vaccination shows strong protection for newborns

Conall Watson, PhD, MSc, consultant epidemiologist at UK Health Security Agency, discusses findings from the United Kingdom’s experience with maternal respiratory syncytial virus (RSV) vaccination, emphasizing both strong public support for immunization and the importance of accessibility and communication in improving uptake.

While most individuals are generally receptive to vaccines, practical barriers—such as scheduling appointments around work and pregnancy—can limit participation. Ensuring convenient access to vaccination services is therefore critical. Additionally, some individuals require reassurance about vaccine safety and necessity, highlighting the key role of health care professionals in providing clear, evidence-based guidance.

A central challenge identified is low public awareness of RSV. Unlike more familiar illnesses such as influenza or whooping cough, RSV and related conditions such as bronchiolitis are not widely understood by parents. Watson notes that improving how health care providers communicate about RSV—particularly framing it as a common and potentially severe cause of chest infections in infants—can help parents better grasp the importance of vaccination and recognize symptoms if their child becomes ill.

The study underscores the substantial benefits of maternal RSV vaccination in preventing severe illness in infants. Advances in medical science over the past decade have transformed the prevention landscape, making immunization a powerful tool to protect newborns. While high-income countries already mitigate many RSV-related deaths through advanced medical care, vaccination offers an additional layer of protection. The potential impact is even greater in low- and middle-income countries, where access to care may be limited and RSV-related mortality remains higher.

Importantly, the research provides new insights into the timing of vaccination. While earlier vaccination within the recommended window remains ideal, the study found that even when the vaccine is administered relatively late in pregnancy—10 to 13 days before birth—it still offers meaningful protection. In these cases, infants experienced approximately a 50% reduction in RSV-related hospitalizations, indicating that sufficient antibody transfer can occur even within a shorter time frame.

Overall, the findings demonstrate that maternal RSV vaccination is highly effective, particularly when administered at least 2 weeks before delivery, and offers a promising strategy to reduce infant hospitalizations. Watson highlights its value as a practical and impactful intervention to improve infant health outcomes, reduce health care burden, and provide reassurance to parents.

This video is part 2 of a 2-part series. Click here for part 1.

No relevant disclosures.

Reference

Maternal RSV vaccination cuts infant hospitalization risk by over 80%, major UKHSA study finds. Beyond. April 17, 2026. Accessed April 17, 2026. https://www.eurekalert.org/news-releases/1123641?